Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSymphony Env. Regulatory News (SYM)

Share Price Information for Symphony Env. (SYM)

Share Price is delayed by 15 minutes
Get Live Data
6.75    0.00 (0.00%)
Bid:
6.00
Ask:
7.50
Spread: 1.50 (25.00%)
Market Cap: £15.95m
SYM Live PriceLast checked at - London Stock Exchange

Intraday Symphony Env. Share Chart

Pre-Close Trading Update

28 Apr 2026 07:00

RNS Number : 1040C
Symphony Environmental Tech. PLC
28 April 2026
Β 

Β 

Β 

This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended ("MAR"). Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

28 April 2026

Β 

Symphony Environmental Technologies plc

("Symphony", the "Company" or the "Group")

FY-2025 pre-close trading update and

Β 

Strong start to FY-2026 - first half profitability

Β 

Symphony Environmental Technologies plc ("Symphony" or the "Group"); global specialists in technologies that make plastic and rubber products "smarter, safer and sustainable", is pleased to provide the following pre-close trading update for the year ended 31 December 2025 ("FY-2025") and notice of FY-2025 results, together with a trading update for the current year to date.

​

FY2025 trading update (subject to audit)

​

Further to the Company's announcement on 17 December 2025, the Board now expects that, as a result of management‑driven strategic change in its Middle East operations, Group revenue for FY-2025 will be higher than previously guided, at approximately Β£5.7 million, with an adjusted loss before interest, tax, depreciation and amortisation ("adjusted LBITDA") broadly comparable to that incurred in the prior year, at approximately Β£0.9 million.

​

Importantly, and as further set out below, sales momentum has not just continued but accelerated during the first four months of FY-2026, running at more than 10 per cent. ahead of the same period last year. Furthermore, margins are also improving due to operational leverage as well as the positive impact of strategic initiatives taken during FY-2025, in particular in the Middle East.

​

In addition to the above adjusted LBITDA, the following one-off costs were incurred during FY-2025 as well as certain asset provisions will be made to the FY-2025 results:

Β· Strategic costs of Β£500,000 primarily in relation to the Middle East but also of certain future corporate initiatives;

Β· Impairment provision of Β£468,000 against development costs for the Group's antimicrobial products due to extended South American customer trials and commercial evaluation; and

Β· Other investment provisions of Β£107,000.

Β 

Β 

The net loss including provisions and strategic costs for FY-2025 is expected to be Β£2.5 million (FY-2024: Β£1.3 million).

​

The Board expects to announce its preliminary results for FY-2025 during the latter half of May.

​

Outlook

​

The Board remains focused on margin quality, disciplined cost control and the commercialisation of higher‑value technologies, rather than short‑term volume growth.

​

That said, it is particularly pleasing that trading in the first four months of 2026 has improved materially. The Group delivered a positive EBITDA in Q1-2026, compared with a loss in the corresponding prior‑year and based on current order patterns, expects to deliver a net profit for H1-2026.

​

Revenues are currently tracking more than 10 per cent ahead of the same period last year. Confirmed orders have been received across all principal markets, particularly Central America. While the timing of shipments remains subject to customer scheduling and customary operational factors, the Board is encouraged by the visibility and quality of the pipeline now in place, which underpins its confidence in the Group's earnings trajectory.

​

The Group continues to monitor the evolving geopolitical situation in the Middle East, which to date has not had a material adverse effect on operations.

​

Enquiries:

Symphony Environmental Technologies Plc

Michael Laurier, CEO

Tel: +44 (0) 20 8207 5900

Ian Bristow, CFO

www.symphonyenvironmental.com

Zeus (Nominated Adviser and Broker)

David Foreman, Emma Burn (Investment Banking)

Tel: +44 (0) 203 829 5000

NOTES TO EDITORS

Β 

Β 

About Symphony Environmental

Β 

Β 

Symphony's d2w masterbatch technology is added to polyethylene (PE) and polypropylene (PP) products at the manufacturing stage at little or no extra cost, and ensures that if they get into the environment at the end of their useful life they will not create microplastics and lie or float around for decades. https://www.symphonyenvironmental.com/technologies/biodegradable-plastic/ Instead they will safely biodegrade, leaving no microplastics or toxicity.

Β 

If they get collected during their programmed life they can be recycled with ordinary PE and PP without separation See https://www.biodeg.org/subjects-of-interest/recycling-2/

Β 

Symphony also supplies a range of plastic technologies under its d2p (designed to protect) brand www.d2p.net to provide protection against insects, viruses, bacteria, fungi, rodents, odours, and fire.Β 

Β 

It has also introduced a new product under its NbR brand https://www.symphonyenvironmental.com/natural-biodegradable-resin/ to reduce the amount of fossil-derived material in plastic products.

Β 

Symphony has a diverse and growing customer-base and has established itself as an international business with over 70 distributors around the world. Products made with Symphony's plastic technologies are now available in nearly 100 countries and in many different product applications. Symphony itself is certified according to ISO9001 and ISO14001.

Β 

Symphony participates in the Committee work of the British Standards Institute (BSI), the American Standards Organisation (ASTM), the European Standards Organisation (CEN), and the International Standards Organisation (ISO).

Β 

Further information on the Group can be found at www.symphonyenvironmental.com and twitter @SymphonyEnv

Β 

See also Symphony on Instagram and Linkedin.

Β 

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
TSTFLFVDSAIDFIR
Date   Source Headline
28th Apr 20267:00 amRNSPre-Close Trading Update
7th Apr 20267:00 amRNS-RHSAC report
23rd Mar 20267:00 amRNSDirector/PDMR dealing - Bed & ISA
18th Feb 20268:28 amRNSNew consultancy agreement and grant of options
12th Jan 20267:00 amRNS-Rd2w Biodegradable Plastic Technology
22nd Dec 20257:00 amRNSCanadian govt policy shift re. single use plastics
22nd Dec 20257:00 amRNSCanadian govt policy shift re. single use plastics
22nd Dec 20257:00 amRNSHolding(s) in Company
22nd Dec 20257:00 amRNSHolding(s) in Company
18th Dec 20252:16 pmRNSStrategic MoU Signed with Arsan Global
18th Dec 20252:16 pmRNSStrategic MoU Signed with Arsan Global
17th Dec 20253:33 pmRNSTrading and Middle East operations update
28th Nov 20257:00 amRNS-RAlignment with BB-REG-NET's Recommendations
26th Nov 202510:25 amRNSExtension to Convertible Loan Agreements
10th Nov 20257:00 amRNS-RNew product launch, South Korea
29th Oct 20257:00 amRNS-RRoyal Society Study on Ocean Biodegradable Plastic
24th Oct 20257:00 amRNS-RCEO speaks at Argus Fertiliser Conference
16th Oct 20257:00 amRNS-RSuccessful attendance at the K-Show
30th Sep 20257:00 amRNSInterim Results for 6 Months Ended 30 June 2025
26th Sep 20257:00 amRNS-RCEO Speaks at US SPE Conference
19th Sep 20254:55 pmRNSEPA Ireland update
23rd Jul 20251:53 pmRNSResult of AGM
23rd Jul 20257:00 amRNSAGM Statement
8th Jul 202510:25 amRNSUpdate on Approval from the Republic of Ireland
25th Jun 20251:49 pmRNSHolding(s) in Company
23rd Jun 202512:37 pmRNSApproval of d2w products in Ireland
18th Jun 20257:00 amRNSPosting of Annual Report and Notice of AGM
12th Jun 20257:00 amRNSPreliminary Results
11th Jun 202510:15 amRNSChange of Subscription Amount
5th Jun 20257:00 amRNSChange of Equity Subscriber
14th May 202511:50 amRNSHolding(s) in Company
8th May 202510:35 amRNSEquity Subscription
10th Apr 20259:00 amRNSExtended Scientific Study on Microplastics in Soil
9th Apr 202510:00 amRNSTransfer of Shareholding and Assignment of CLAs
11th Mar 20257:00 amRNS-RStudy Findings - No Trace of Microplastics
10th Mar 20252:21 pmRNSHolding(s) in Company
3rd Mar 20257:00 amRNS-RRuling on Biodegradable Plastic Legislation
23rd Dec 202412:39 pmRNSOption amendments & grant of options
1st Nov 202411:15 amRNSGrant of Options
9th Sep 20247:00 amRNSInterim Results for 6 Months Ended 30 June 2024
23rd Aug 20247:00 amRNSNotice of Results and Investor Presentation
28th Jun 202412:49 pmRNSResult of AGM
28th Jun 20247:00 amRNSAGM Statement
6th Jun 20243:33 pmRNSPosting of Annual Report and Notice of AGM
6th Jun 20243:29 pmRNSPreliminary Results
23rd Apr 20244:36 pmRNSHolding(s) in Company
19th Apr 202411:16 amRNSResult of GM
3rd Apr 20242:00 pmRNSDirector dealing
28th Mar 20244:23 pmRNSResult of PrimaryBid Offer
28th Mar 20242:18 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.